News | September 20, 2024
Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
This license will enable Abbott to enhance access to this novel therapy to more patients across India
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
The recent inspection covered both cGMP and PAI processes
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Subscribe To Our Newsletter & Stay Updated
